Systemic sclerosis
Drug research and approvals for systemic sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 154 studies of systemic sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, and FDA has 2 approved and 51 open orphan designations naming it.
- Recruiting worldwide: 154
- Trials authorized in Canada: 26
- FDA orphan approvals: 2
- EU medicines: 0
Recruiting Now
Newest start dates first, of 154 recruiting on ClinicalTrials.gov ↗- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesNCT05029336 · Phase 2 · Stephan Grupp MD PhD · starts Nov 1, 2026
- Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)NCT07650565 · Not applicable · University Hospital, Montpellier · starts Oct 27, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it…NCT07649265 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 24, 2026
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically…NCT07691970 · Phase 3 · AstraZeneca · starts Aug 31, 2026
- A Study to Test CRT-402 in Refractory Autoimmune DiseaseNCT07778446 · Phase 1 / Phase 2 · Myeloid Therapeutics · starts Aug 26, 2026
- A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisNCT07497087 · Phase 3 · Boehringer Ingelheim · starts Jul 27, 2026
- US Zamto-cel Autoimmune DiseasesNCT06708845 · Phase 1 · Miltenyi Biomedicine GmbH · starts Jul 1, 2026
- Immun4Cure Cohort of Autoimmune DiseasesNCT07515638 · Not reported · University Hospital, Montpellier · starts Jun 23, 2026
Trials Authorized in Canada
The 10 newest of 26; search them all in Canada trials| May 12, 2026 | Immunomodulatory maintenance therapy post-autologous hematopoietic stem cell transplantation for prevention of systemic sclerosis relapse: a pilot randomized…MYCOPHENOLATE | OTTAWA HOSPITAL RESEARCH INSTITUTE | Pending |
| Apr 23, 2026 | A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis…NERANDOMILAST (BI 1015550) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Pending |
| Mar 6, 2026 | A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of bms-986353, cd19-targeted nex-t car t cells, versus standard of care…BMS-986353 (CC-97540) / ROACTEMRA (TOCILIZUMAB) / TRUXIMA (TRITUXIMAB) /… | Bristol-Myers Squibb | Pending |
| Sep 23, 2025 | A phase¿2, multi-center study consisting of a randomized, double-blind, placebo-controlled period, followed by an open-label extension period, to assess the…TIBULIZUMAB (ZB-106) | ZURA BIO INC. | Closed |
| Aug 20, 2025 | An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ild) associated with systemic…BENLYSTA | GSK | Pending |
| Dec 20, 2024 | A phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of…YTB323 (RAPCABTAGENE AUTOLEUCEL) | Novartis Pharmaceuticals Corporation | Pending |
| Jul 23, 2024 | Conquest platform clinical study for conquering scleroderma: a multicenter, double-blind, randomized, placebo-controlled, phase 2b platform clinical study to…NERANDOMILAST (BI 1015550)/ AMLITELIMAB (SAR445229) | SCLERODERMA RESEARCH FOUNDATION, INC. | Closed |
| Aug 28, 2023 | Randomized double-blind placebo-controlled clinical trial to assess the efficacy of mycophenolate mofetil in subclinical interstitial lung disease associated…MYCOPHENOLATE | SANTÉ QUÉBEC¿- CENTRE HOSPITALIER DE L’UNIVERSITÉ DE MONTRÉAL | Ongoing |
| Aug 24, 2023 | A phase 2/3, randomized, double-blind, placebo, controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously…BELIMUMAB | GSK | Pending |
| May 31, 2023 | A multicenter, randomized, parallel-group, double-blind, two¿ arm, phase III study to evaluate the safety and efficacy of anifrolumab compared with placebo in…SAPHNELO | AstraZeneca Pharmaceuticals LP | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 53| Mar 4, 2021 | Actemraslowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease | Genentech, Inc. | Approved |
| Sep 6, 2019 | OFEVOFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung… | Boehringer Ingelheim Pharmaceuticals, Inc. | Approved |
| Aug 17, 2026 | botulinum toxin type A (BTX-A)treatment of systemic sclerosis (SSc) | ARCK Biologics, INC. | Designated |
| Mar 9, 2026 | nerandomilasttreatment of systemic sclerosis | Boehringer Ingelheim Pharmaceuticals, Inc, (BIPI) | Designated |
| Jan 13, 2026 | nemolizumabtreatment of systemic sclerosis | Galderma Research and Development, LLC | Designated |
| Dec 19, 2025 | autologous CD3+ T cells expressing CD19 chimeric antigen…treatment of systemic sclerosis | Juno Therapeutics, Inc., a subsidiary of Bristol Myers Squibb | Designated |
| Oct 16, 2025 | blinatumomabtreatment of systemic sclerosis | Amgen Inc. | Designated |
| Aug 11, 2025 | 2-[1-(3-{6-[(1E)-(hydroxyimino)methyl]-5-methyl-4-oxo-7-prop…treatment of digital ulcers in systemic sclerosis | Topadur Pharma AG | Designated |
| Jan 31, 2025 | artesunatetreatment of systemic sclerosis | Artasome Therapeutics, LLC | Designated |
| Oct 18, 2024 | anti-ephrinB2 humanized IgG1 monoclonal antibodytreatment of systemic sclerosis (SSc) | Mediar Therapeutics, Inc. | Designated |
| Sep 20, 2024 | autologous anti-CD19 CAR T cell immunotherapytreatment of systemic sclerosis | Kyverna Therapeutics, Inc. | Designated |
| Aug 19, 2024 | cilnidipinetreatment of systemic sclerosis | Aisa Pharma Inc. | Designated |
| Aug 5, 2024 | (E)-N-(6-(piperidin-1-ylmethyl)-1-propyl-1,3-dihydro-2H-benz…Treatment of systemic sclerosis | EydisBio, Inc. | Designated |
| Mar 21, 2024 | pyridine derivative containing pyridazine that inhibits…Treatment of Systemic Sclerosis | Boehringer Ingelheim Pharmaceuticals, Inc. | Designated |
| Mar 21, 2024 | small synthetic peptide based on a sequence found in the…Treatment of Systemic Sclerosis | BLR Bio LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA